HY001 (cUTI program)
Complicated Urinary Tract Infection (cUTI)
Phase 3 (planned)Active
Key Facts
Indication
Complicated Urinary Tract Infection (cUTI)
Phase
Phase 3 (planned)
Status
Active
Company
About Helperby Therapeutics
Helperby Therapeutics is pioneering a unique strategy to address the global crisis of anti-microbial resistance by creating synergistic combinations of approved antibiotics. Founded in 2014 by renowned infectious disease expert Prof. Sir Anthony Coates, the company's platform identifies drug pairings that are significantly more potent than single agents and can treat highly resistant bacteria. Its lead programs target complicated urinary tract and skin infections, with a Phase I study completed, and the company is advancing towards Phase III trials. Helperby's model focuses on developing affordable, globally accessible treatments through established regulatory pathways for drug combinations.
View full company profile